# Obesity Market Epidemiology Report 2025-2035: Drugs, Pipeline Therapies, and Regional Outlook The [obesity market](https://www.imarcgroup.com/obesity-market) size reached a value of USD 17.1 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 76.6 million by 2035, exhibiting a growth rate (CAGR) of 14.62% during 2025-2035. Obesity and weight management-related markets operate as dynamic and multifaceted industries addressing a huge public health problem. The sector integrates all kinds of treatment methodologies: lifestyle counseling and advanced pharmacotherapies-medical devices-behavioral interventions and surgical procedures. Over the past two to three decades, the market has undergone fundamental changes due to a faster rise in obesity levels worldwide, which was prompted by changes in dietary patterns, an increasingly sedentary lifestyle, and the onset of urbanization-from traditional interventions into a full-fledged ecosystem of established and emerging therapies. Obesity has been growing big and challenging by the whole range of obstacles. Cost barriers of out-of-the-pocket-dependent mainly with insurance, therefore low nurturing, meaning that fewer than 30 percent of the patients probably continue the treatment, in cases it is financially heavy, for one year after treatment. Other challenges have been supply shortages for some of the sought GLP-1s. Commonly observed side effects of discontinuation are nausea, constipation, and diarrhea, which prompt some concerns about their long-term safety and the need for continuous drug use. Another area that forms yet another glaring chasm is the provision of integrated care and nutrition counseling; drugs are most effective when combined with lifestyle changes, yet patients do not always receive the same level of support, potentially leading to nutrients deficiency and, paradoxically, weight regain when they stop taking the medications. Request to get a PDF Sample Report: [https://www.imarcgroup.com/obesity-market/requestsample](https://www.imarcgroup.com/obesity-market/requestsample) The report also provides a detailed analysis of the current obesity marketed drugs and late-stage pipeline drugs. In-Market Drugs Drug Overview Mechanism of Action Regulatory Status Clinical Trial Results Drug Uptake and Market Performance Late-Stage Pipeline Drugs Drug Overview Mechanism of Action Regulatory Status Clinical Trial Results Drug Uptake and Market Performance Buy the full Obesity Market Epidemiology Report: [https://www.imarcgroup.com/checkout?id=27912&method=809](https://www.imarcgroup.com/checkout?id=27912&method=809) Analysis Covered Across Each Country Historical, current, and future epidemiology scenario Historical, current, and future performance of the obesity market Historical, current, and future performance of various therapeutic categories in the market Sales of various drugs across the obesity market Reimbursement scenario in the market In-market and pipeline drugs Competitive Landscape The competitive landscape of the obesity market has been studied in the report with the detailed profiles of the key players operating in the market. Roche VIVUS Currax Pharma Novo Nordisk Amgen Eli Lilly and Company Boehringer Ingelheim Carmot Therapeutics 7 Major Countries Covered United States Germany France United Kingdom Italy Spain Japan About Us: IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact US: IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: [sales@imarcgroup.com](mailto:sales@imarcgroup.com) Tel No:(D) +91 120 433 0800 United States: +1-631-791-1145